Spots Global Cancer Trial Database for A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Official Title: A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Study ID: NCT01456689
Conditions
Study Description
Brief Summary: The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with Multiple Myeloma (MM).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Chicago, Illinois, United States
Novartis Investigative Site, Ann Arbor, Michigan, United States
Novartis Investigative Site, Rochester, Minnesota, United States
Novartis Investigative Site, Houston, Texas, United States
Novartis Investigative Site, Heidelberg, , Germany
Novartis Investigative Site, Kiel, , Germany
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
